Danaher (DHR) Q3 2026 Earnings Call: Q&A Summary

Q: Doug Schenkel with UBS asked how the new CEO balances the company's legacy of operational excellence with the need for change.

A: Julie Montgomery stated she intends to preserve the operating company structure while working in a more connected way to make the full power of Danaher accessible to customers. She identified commercial excellence, strategy-led innovation, talent, and capital allocation as the key priorities.

Q: Doug Schenkel with UBS asked for the biggest near-term priority and how investors should measure progress.

A: Julie Montgomery identified commercial excellence as the top priority, noting that investors should look for higher core growth and unambiguous share gain as the primary report card.

Q: Vijay Kumar with Evercore ISI asked if bioprocessing should be a high single-digit or low double-digit growth business in 2027.

A: Matt Gugino reiterated the 2026 full-year expectation of mid-single-digit core growth, noting that Q3 was at the upper end of that range. He added that the long-term view for the business is high single-digit growth.

Q: Casey Woodring with JPMorgan asked for details on equipment order growth and the impact of reshoring.

A: Matt Gugino noted that equipment orders are in the strong double-digit range. Julie Montgomery added that reshoring is a 2028-plus event for the P&L.

Q: Vijay Kumar with Evercore ISI asked about M&A strategy and if Masimo signals a shift toward medtech.

A: Julie Montgomery stated that M&A remains the bias for capital allocation and that Masimo is viewed as a continuous diagnostic play that is strategically compounding with the diagnostics business.

Q: Scott Davis with Melius Research asked how to drive M&A consistency and avoid past mistakes without freezing the process.

A: Julie Montgomery emphasized that the company will continue to focus on strategically compounding M&A with robust return profiles and has learned from recent performance.

Q: Tycho Peterson with Jefferies asked why 4% to 5% core growth is the starting point for 2027.

A: Julie Montgomery explained that this is a reasonable starting point based on current market conditions, and the company will provide a more detailed outlook in January.

Q: Tycho Peterson with Jefferies asked about the $100 million cut to respiratory guidance and the endemic rate.

A: Julie Montgomery stated the company is planning for $1.5 billion in respiratory revenue for this year and next, noting it is prudent to plan for a typical flu season.

Q: Jack Meehan with Research asked about the implications of AI for Danaher and its deployment with the Danaher Business System.

A: Julie Montgomery described AI as a significant long-term opportunity, noting that the company has the necessary instruments, consumables, automation, software, and scale to lead in this area.

Q: Jack Meehan with Research asked about the strategy behind the NVIDIA and autonomous lab announcements.

A: Julie Montgomery explained that the company is connecting AI to the physical experiment to create a design, make, and test loop, while the NVIDIA collaboration helps accelerate AI adoption through edge computing and digital twins.

Q: Scott Davis with Melius Research asked how the company plans to drive change in commercial execution.

A: Julie Montgomery stated she is focused on the commercial standard condition and setting simple expectations for sales teams, while also experimenting with AI to coach and inspect results.

Q: Casey Woodring with JPMorgan asked about current trends in the Masimo business and its contribution for next year.

A: Julie Montgomery reported that Masimo delivered high single-digit growth in Q3 and that integration is progressing well with commercial synergies and lean manufacturing improvements.

Q: Elizabeth Koslosky with Goldman Sachs asked about the recovery status in academic, biotech, and industrial markets.

A: Julie Montgomery noted that Life Sciences grew 4.5%, with large pharma and biopharma remaining robust, biotech funding reading through, and academic demand improving sequentially despite remaining below historic levels.